Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Shareholders are suing Novo Nordisk, alleging the company misled them about the clinical trial design for its next-generation obesity drug, CagriSema. A US federal judge has allowed parts of the lawsuit to proceed, specifically claims that Novo was not transparent about the trial's flexible dosing protocol, which led to disappointing results and a significant drop in stock value.

This Wire brief sits within Fusion42's coverage of Drug Discovery.